CureVac posts positive pre-clinical data for Covid-19 vaccine
October 23 2020 03:13 PM
An employee of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine
An employee of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus disease at a laboratory in Tuebingen, Germany, March 12, 2020

Reuters/Berlin

German biotech company CureVac said on Friday its potential vaccine against the coronavirus induced an immune response in pre-clinical animal studies.
CureVac said the potential vaccine, known as CVnCoV, produced neutralising antibodies and activated T-cells in hamsters and mice.
The vaccine, which is being tested in humans in early and mid-stage trials, also protected the lungs of hamsters when they were exposed to a live virus, the company said.
"The pre-clinical data published today show that our Covid-19 vaccine candidate has the potential to induce an efficacious and balanced immune response, mimicking the natural immune defence and providing lung protection in a relevant challenge model,” said CureVac Chief Technology Officer Mariola Fotin-Mleczek. 



There are no comments.

LEAVE A COMMENT Your email address will not be published. Required fields are marked*
MORE NEWS

HAPPENING IN DOHAMore